Decavac

Decavac is a Tetanus and Diphtheria Toxoids Adsorbed (Td) vaccine indicated for active immunization against tetanus and diphtheria in individuals aged 7 years and older. Originally developed and manufactured by Sanofi, it consists of a combination of purified tetanus toxoid and purified diphtheria toxoid adsorbed onto an aluminum salt adjuvant (typically aluminum phosphate) to enhance the immune response. The vaccine works by inducing the production of specific neutralizing antibodies (antitoxins) that protect the recipient from the systemic effects of toxins produced by *Clostridium tetani* and *Corynebacterium diphtheriae*. In clinical research, specifically in trials sponsored by GSK, Decavac has served as an active comparator to evaluate the safety and immunogenicity of Tdap vaccines (which include a pertussis component), such as Boostrix, particularly in older adult populations. Although the trial context may involve pertussis indications, Decavac itself is a divalent vaccine and does not contain a pertussis component. Decavac was previously marketed in the United States but has since been discontinued and replaced by other Td formulations like Tenivac.

Brand names

Decavac

Other names

Tetanus and Diphtheria Toxoids AdsorbedTd vaccine